Trump’s America Slashes Drug Prices as Biden’s Bureaucratic Scheme Finally Gets Fixed

In a stunning victory for American seniors—and a major embarrassment for the Biden-era bureaucrats who created this mess—Medicare officials on Nov. 25 announced the newly negotiated prices for 15 of the nation’s most expensive drugs, projecting a massive 44% price drop and $12 billion in savings. These reductions, scheduled for early 2027, come as President Trump’s administration forces real accountability and pushes back against the bloated pharmaceutical-government complex.

The annual “negotiations,” originally born from Biden’s 2022 Inflation Reduction Act, were toothless until now. Under President Trump’s renewed leadership and a Health Secretary who actually works for the people—Robert F. Kennedy Jr.—the CMS is finally using its authority to lower costs instead of protecting drug-company profits.

Major cuts include Novo Nordisk’s semaglutide drugs—Ozempic and Wegovy—dropping to $274 a month, a steep fall from last year’s $428 net price and far below the shocking $959 list price.

“President Trump directed us to stop at nothing to lower health care costs for the American people,” Secretary Kennedy said. “As we work to Make America Healthy Again, we will use every tool to deliver affordable care to seniors.”

Negotiated savings now range from 38% to 85%, proving once again: when Trump leads, Americans win—big.